Truist cuts Regeneron stock price target on biosimilar concerns By Investing.com - ca.investing.com

Regeneron reported Phase 3 China topline for olatorepatide showing up to 19% weight loss over 48 weeks and up to 97% of patients >5% weight loss; multiple firms raised/initiated price targets (Jefferies $890, TD Cowen $880, Piper Sandler $875). Truist lowered its price target to $801 from $818 but kept a Buy, citing biosimilar risk to the Eylea franchise and potential payer-driven share loss in 2026. Shares trade at $770 (near a 52-week high of $821) after a 34% six-month rally, while InvestingPro fair value is $929, implying upside. Key risk: biosimilar entry and payer actions could materially erode Eylea/Eylea HD market share and valuation.

Analysis

Regeneron’s core ophthalmology franchise faces a classic pricing-and-access vector: third-party entrants can win share rapidly if payers move to formulary/tendering that prioritizes price over incremental clinical convenience. If entrants launch at a 30-50% price discount and achieve 30-40% uptake within 12-24 months, modeled peak sales for the franchise could compress by ~20-35%, translating into a 200–400 bps hit to corporate EBIT margin assuming limited offset from cost cuts or mix improvements.

Device and CMO ecosystems are the hidden lever. A rapid shift to alternative presentations (prefilled devices or biosimilar supply chains) will create concentrated, lumpy demand for fill/finish and device manufacturing capacity — beneficiaries include specialty CMOs and silicone/syringe suppliers, while incumbent in-house manufacturing or single-source suppliers face stranded capacity and margin pressure in the first 6–18 months of the transition.

Catalysts that will re-rate the story are payer contracting decisions, real-world switch rates from clinicians, and any proprietary formulation differentiation that demonstrably reduces total cost of care. Near-term volatility is likely to spike ahead of contract rounds and device approvals; a downside re-pricing can be sharp (weeks–months) if payers openly adopt tendering, while reversal requires sustained evidence of superior outcomes or material price concessions that restore access economics over multiple quarters.

Key Decisions for Investors

• Buy asymmetric downside protection: Buy a 6–12 month put spread on REGN with strikes ~15–25% OTM financed by selling a nearer-term 30–45 day call (collect IV). Rationale: protects against a 20–40% franchise shock at a ~2–1 payoff while monetizing near-term premium; cost should be <3–6% of notional.
• Construct a funded long convexity stance: Sell 1–2x short-dated (30–60 day) 10% OTM calls on REGN to fund purchase of 18–24 month LEAP calls 20–30% OTM. Timeframe: 12–24 months. Risk/reward: limited carry income vs large upside if pipeline or pricing actions re-accelerate share; breakeven materially lower than outright LEAP purchase.
• Relative-value pair: Short REGN equity (6–12 month view) and go long a diversified biotech ETF (IBB or XBI) to isolate franchise-specific downside versus sector exposure. Size the short to be 30–40% of portfolio beta to avoid market-directional skew; target a 20–30% spread unwind as payers finalize contracts.
• Directional supplier long: Buy small to medium-cap positions in specialty CMOs/device manufacturers with demonstrated fill/finish capacity (6–18 month horizon). Rationale: they stand to capture outsized incremental revenue even if the incumbent franchise declines; target names with >30% revenue exposure to ophthalmic injectables and 15–20% EBITDA expansion potential under re-shoring scenarios.